{"id":246070,"date":"2012-07-03T20:16:21","date_gmt":"2012-07-03T20:16:21","guid":{"rendered":"http:\/\/www.eugenesis.com\/prospective-comparison-of-oncotype-dx-and-central-pathology-assessment-shows-her2-discordance\/"},"modified":"2012-07-03T20:16:21","modified_gmt":"2012-07-03T20:16:21","slug":"prospective-comparison-of-oncotype-dx-and-central-pathology-assessment-shows-her2-discordance","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/prospective-comparison-of-oncotype-dx-and-central-pathology-assessment-shows-her2-discordance.php","title":{"rendered":"Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance"},"content":{"rendered":"<p><p>    Douglas Kell has been reappointed as chief    executive and deputy chair of the UK Biotechnology and    Biological Sciences Research Council, the Minister for    Universities and Science David Willetts said    this week.  <\/p>\n<p>    Kell has held the top post at BBSRC since 2008, and before that    he was director of the Manchester Centre for    Integrative Systems Biology. He also has served as    director of research at the Institute of Biological    Sciences at the University of    Aberystwyth, and he was a founding director of    Aber Instruments. His research has included a    range of topics including systems biology, analytical    chemistry, and biochemical and data modeling.  <\/p>\n<p>    The Institute for Systems Biology has    appointed Robert Lipshutz to be chief business    officer and senior VP for strategic partnerships. Lipshutz    spent nearly two decades at Affymetrix in various roles    focusing on business development, licensing, diagnostics, and    emerging markets, and most recently as senior VP for corporate    development.  <\/p>\n<p>    Verinata Health CEO Caren    Mason has resigned but will continue to provide the    company with consultative services. Mason joined Verinata in    November 2010. She was previously the president and CEO of    Quidel, president and CEO of    MiraMedica, CEO of eMed    Technologies, and general manager of GE    Healthcare. The firm plans to recruit a new CEO.  <\/p>\n<\/p>\n<p>See original here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.genomeweb.com\/mdx\/prospective-comparison-oncotype-dx-and-central-pathology-assessment-shows-her2-d\" title=\"Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance\">Prospective Comparison of Oncotype DX and Central Pathology Assessment Shows HER2 Discordance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Douglas Kell has been reappointed as chief executive and deputy chair of the UK Biotechnology and Biological Sciences Research Council, the Minister for Universities and Science David Willetts said this week. Kell has held the top post at BBSRC since 2008, and before that he was director of the Manchester Centre for Integrative Systems Biology. He also has served as director of research at the Institute of Biological Sciences at the University of Aberystwyth, and he was a founding director of Aber Instruments.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/prospective-comparison-of-oncotype-dx-and-central-pathology-assessment-shows-her2-discordance.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-246070","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246070"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=246070"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/246070\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=246070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=246070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=246070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}